Pfizer announces settlement of Detrol LA patent litigation with Mylan

Download PDF Copy

Sep 7 2012

NewsGuard 100/100 Score

Pfizer Inc. announced that it has settled its litigation against Mylan Inc. and Mylan Pharmaceuticals Inc. relating to Pfizer's patents covering Detrol LA® (tolterodine tartrate) extended-release capsules.

As a result of this settlement, and past settlements related to these patents, Pfizer expects generic competition for Detrol LA® to commence in the United States no earlier than January 1, 2014, except in certain limited circumstances, and no later than March 1, 2014.

The terms of the settlement agreement are otherwise confidential.

A generic version of Detrol LA® has not been approved to date.

The company indicated that this settlement does not result in any change in its 2012 financial guidance previously updated on August 13, 2012.

Source:

Pfizer Inc.

Posted in: Medical Patent News | Pharmaceutical News

Tags: Pharmaceuticals

Comments (0)

Download PDF Copy

Suggested Reading

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

New biomarkers offer hope for early detection and prevention of Alzheimer's

New biomarkers offer hope for early detection and prevention of Alzheimer's

SU2C announces grants to support cutting-edge research in a variety of cancers

SU2C announces grants to support cutting-edge research in a variety of cancers

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Urine RNA analysis shows promise for detecting genitourinary diseases

Urine RNA analysis shows promise for detecting genitourinary diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Tiny molecule offers hope in reducing opioid side effects